Literature DB >> 16177255

Immune response as a biomarker for cancer detection and a lot more.

Olivera J Finn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16177255     DOI： 10.1056/NEJMe058157

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  36 in total

1.  Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

Authors:  Dennis J O'Rourke; Daniel A DiJohnson; Robert J Caiazzo; James C Nelson; David Ure; Michael P O'Leary; Jerome P Richie; Brian C-S Liu
Journal:  Clin Chim Acta       Date:  2011-11-29       Impact factor: 3.786

2.  Translation research in prostate cancer.

Authors:  Danil V Makarov; Alan W Partin
Journal:  Rev Urol       Date:  2006

3.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

4.  Gut immunoglobulin alpha anti-glycan binding profiles as a research tool for local disease detection.

Authors:  Joseph J Otto; Crystal L Daniels; Lindsay N Schambeau; Brittany N Williams; Jana M Rocker; Lewis K Pannell
Journal:  Glycoconj J       Date:  2018-06-09       Impact factor: 2.916

5.  Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients.

Authors:  Julia Shih; Munira Rahman; Quang T Luong; Shirley H Lomeli; Joseph Riss; Robert M Prins; Ali O Gure; Gang Zeng
Journal:  Am J Clin Exp Immunol       Date:  2014-08-15

6.  Comparison of candidate serologic markers for type I and type II ovarian cancer.

Authors:  Dan Lu; Elisabetta Kuhn; Robert E Bristow; Robert L Giuntoli; Susanne Krüger Kjær; Ie-Ming Shih; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2011-06-24       Impact factor: 5.482

7.  Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.

Authors:  Jun Dong; Bo-hang Zeng; Li-hua Xu; Jun-ye Wang; Man-zhi Li; Mu-sheng Zeng; Wan-li Liu
Journal:  J Transl Med       Date:  2010-09-03       Impact factor: 5.531

8.  Antibody profiling with protein antigen microarrays in early stage cancer.

Authors:  Brian C-S Liu; Daniel A Dijohnson; Dennis J O'Rourke
Journal:  Expert Opin Med Diagn       Date:  2012-03-22

Review 9.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

10.  Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.

Authors:  Ji Qiu; Gina Choi; Lin Li; Hong Wang; Sharon J Pitteri; Sandra R Pereira-Faca; Alexei L Krasnoselsky; Timothy W Randolph; Gilbert S Omenn; Cim Edelstein; Matt J Barnett; Mark D Thornquist; Gary E Goodman; Dean E Brenner; Ziding Feng; Samir M Hanash
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.